These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38587429)

  • 21. Noninvasive Indices of MASLD Are Associated With Hypogonadism in Male Patients With Type 2 Diabetes Mellitus.
    Caretta N; Scafa R; Graziani A; Crepaldi MC; Vedovato M; Avogaro A; Ferlin A
    J Clin Endocrinol Metab; 2024 Jan; 109(2):e522-e530. PubMed ID: 37795977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persons with metabolic dysfunction-associated steatotic liver disease are at increased risk of severe depression.
    Åström H; Shang Y; Hagström H; Wester A
    Liver Int; 2024 Oct; 44(10):2551-2563. PubMed ID: 38949395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between Alcohol Consumption and Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Alcohol Flushing Response in Men: The Korea National Health and Nutrition Examination Survey 2019-2021.
    Kang DE; Oh SN
    Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
    Clayton-Chubb D; Kemp WW; Majeed A; Lubel JS; Woods RL; Tran C; Ryan J; Hodge A; Schneider HG; McNeil JJ; Roberts SK
    Liver Int; 2024 Jan; 44(1):39-51. PubMed ID: 37698034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic-associated steatotic liver disease and risk of Alzheimer's disease: a real-world retrospective cohort study.
    Zhang J; Wang W; Hou X; Wu J; Wang Y; Fan J; Zhang Z; Yuan Z; Sun C; Lu B; Zheng J
    Front Endocrinol (Lausanne); 2024; 15():1451908. PubMed ID: 39296714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poorly controlled pediatric type 1 diabetes mellitus is a risk factor for metabolic dysfunction associated steatotic liver disease (MASLD): An observational study.
    Koutny F; Wiemann D; Eckert A; Meyhöfer S; Fritsch M; Pappa A; Wiegand S; Weyer M; Wurm M; Weghuber D; Holl RW
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1027-1037. PubMed ID: 38558281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers.
    Mantovani A; Lonardo A; Stefan N; Targher G
    Metabolism; 2024 Nov; 160():156014. PubMed ID: 39182602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.
    Tamaki N; Kimura T; Wakabayashi SI; Umemura T; Kurosaki M; Loomba R; Izumi N
    Aliment Pharmacol Ther; 2024 Jul; 60(1):61-69. PubMed ID: 38664876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adherence to a healthy lifestyle including sleep and sedentary behaviors and risk of metabolic dysfunction-associated steatotic liver disease in Chinese adults.
    Zhang S; Huo Z; Borné Y; Meng G; Zhang Q; Liu L; Wu H; Gu Y; Sun S; Wang X; Zhou M; Jia Q; Song K; Ma L; Qi L; Niu K
    Prev Med; 2024 Jul; 184():107971. PubMed ID: 38657685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between fatty liver index and risk of end-stage renal disease stratified by kidney function in patients with type 2 diabetes: A nationwide population-based study.
    Chung GE; Han K; Lee KN; Bae JH; Yang SY; Choi SY; Yim JY; Heo NJ
    Diabetes Metab; 2023 Jul; 49(4):101454. PubMed ID: 37244418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study.
    Aboona MB; Faulkner C; Rangan P; Ng CH; Huang DQ; Muthiah M; Nevah Rubin MI; Han MAT; Fallon MB; Kim D; Chen VL; Wijarnpreecha K
    Liver Int; 2024 Jun; 44(6):1316-1328. PubMed ID: 38407554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Machine Learning Identifies Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Diabetes Mellitus.
    Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH
    J Clin Endocrinol Metab; 2024 Jul; 109(8):2029-2038. PubMed ID: 38330228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis.
    Lv Q; Zhao H
    Ann Med; 2024 Dec; 56(1):2306192. PubMed ID: 38253023
    [No Abstract]   [Full Text] [Related]  

  • 37. Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality.
    Oh R; Kim S; Cho SH; Kim J; Lee YB; Jin SM; Hur KY; Kim G; Kim JH
    Diabetes Metab J; 2024 Aug; ():. PubMed ID: 39197834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of health checkup-based indices in identifying metabolic dysfunction-associated steatotic liver disease.
    Miwa T; Tajirika S; Imamura N; Adachi M; Horita R; Hanai T; Ng CH; Siddiqui MS; Fukao T; Shimizu M; Yamamoto M
    JGH Open; 2024 Jun; 8(6):e13110. PubMed ID: 38895100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of metabolic dysfunction-associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study.
    Kim K; Lee Y; Lee JS; Kim MN; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Jung I; Lee HW
    J Gastroenterol Hepatol; 2024 Dec; 39(12):2845-2852. PubMed ID: 39343427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
    Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.